A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Cream, 3.75% and Zyclara™ (Imiquimod) Cream, 3.75% in Subjects With Actinic Keratoses
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of Generic Imiquimod Cream, 3.75% and Zyclara™ (Imiquimod) Cream, 3.75% in Subjects With Actinic Keratoses
Sponsor: Actavis Mid-Atlantic LLC
A NA clinical study on Actinic Keratoses, this trial is completed. The trial is conducted by Actavis Mid-Atlantic LLC and has accumulated 6 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
-
Feb 2017 — Jun 2018 [monthly]
Completed NA
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed NA
First recorded
Feb 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Actavis Mid-Atlantic LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Albuquerque, United States , Arlington Heights, United States , Austin, United States , Birmingham, United States , Boise, United States , Charlotte, United States , Cincinnati, United States , Clinton Township, United States , Evansville, United States , Fort Washington, United States and 9 more locations